Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Operating Leases (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Operating Leases data on record, last reported at $25.0 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 17.1% year-over-year to $25.0 million; the TTM value through Sep 2025 reached $25.0 million, down 17.1%, while the annual FY2024 figure was $28.9 million, 13.86% down from the prior year.
  • Operating Leases reached $25.0 million in Q3 2025 per SNTI's latest filing, down from $31.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $37.9 million in Q1 2023 and bottomed at $21.0 million in Q4 2021.
  • Average Operating Leases over 5 years is $31.2 million, with a median of $31.3 million recorded in 2024.
  • Peak YoY movement for Operating Leases: soared 67.25% in 2022, then decreased 19.01% in 2024.
  • A 5-year view of Operating Leases shows it stood at $21.0 million in 2021, then soared by 67.25% to $35.1 million in 2022, then decreased by 4.46% to $33.5 million in 2023, then fell by 13.86% to $28.9 million in 2024, then dropped by 13.58% to $25.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $25.0 million in Q3 2025, $31.3 million in Q2 2025, and $27.6 million in Q1 2025.